BRACCO IMAGING LAUNCHES NEW SUBSIDIARY, BLUE EARTH THERAPEUTICS, TO ADVANCE DEVELOPMENT OF NEXT GENERATION THERAPEUTIC RADIOPHARMACEUTICAL TECHNOLOGY

MILAN, March 1, 2022 /PRNewswire/ -- Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer. Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology.

"We are increasingly committed to precision medicine," says Fulvio Renoldi Bracco, Vice-Chairman of the Board & CEO of Bracco Imaging S.p.A., the world leader in diagnostic imaging. "Blue Earth Therapeutics will leverage the support of all Bracco Imaging's global capabilities and complementary portfolio to strengthen its high-value technology platform for innovative therapeutic radiopharmaceuticals, to care for cancer patients around the world. The creation of Blue Earth Therapeutics marks an exciting new direction for us in addressing important unmet needs in patient health."

Theranostic radiohybrid (rh) PSMA pharmaceuticals have potential utility in both diagnostic imaging and therapy of prostate cancer. They can be labelled with either a diagnostic or a therapeutic radioisotope. If approved, these innovative investigational compounds offer the possibility of personalized medicine for men with prostate cancer by directing therapies specifically to the PSMA disease target.

Blue Earth Therapeutics has developed a highly optimized lead rhPSMA therapeutic compound, with a focus to increase the delivery of therapeutic radiation to kill tumors and minimize radiation exposure to healthy key organs such as kidney and bone marrow. Administering the lowest reasonably achievable radiation dose to normal tissues is a key principle of nuclear medicine, and particularly important when considering that therapeutic PSMA radioligands may be used earlier in prostate cancer disease progression in the future. 

"We are very excited to launch Blue Earth Therapeutics during this renaissance of nuclear medicine, with the goal to fulfill the promise of targeted radiopharmaceutical therapy in treating patients with life-threatening disease," says David Gauden, D. Phil., Chief Executive Officer, Blue Earth Therapeutics. "Blue Earth Therapeutics has demonstrable radiopharmaceutical therapy development expertise, and our initial efforts will address the growing patient treatment needs in prostate cancer, where we are currently advancing our flagship, next generation, 177Lu beta-emitting product candidate into clinical trials in the United States and European Union. Initial investment in our company is provided by our founding shareholder, Bracco Imaging, and there are significant shared synergies with our sister company, Blue Earth Diagnostics, which together provide Blue Earth Therapeutics a solid platform for future success. Near-term opportunities for further investment in the Blue Earth Therapeutics portfolio may include additional indications within prostate cancer for our initial product as well as development of alpha-emitting radiotherapeutics and development and licensing of new compounds in other cancer areas."

Blue Earth Therapeutics intends to build a pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. The company is leveraging its radiopharmaceutical development experience, as demonstrated by the rapid success of its sister company Blue Earth Diagnostics, acquired by Bracco Imaging in 2019, to advance its nuclear medicine portfolio and apply its expertise to the world of next generation therapeutic radiopharmaceuticals.

Bracco Imaging
Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine. In 2019 Bracco Imaging also enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. The company is active in molecular imaging with innovative agents for positron emission tomography (PET) in patients with suspected recurrent prostate cancer. To learn more, visit www.braccoimaging.com.

Blue Earth Therapeutics
Blue Earth Therapeutics, an indirect subsidiary of Bracco Imaging, S.p.A., is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start-up experience, the company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is based in Oxford, UK. For more information, please visit: https://www.blueearththerapeutics.com.

Bracco Imaging Press Office
Micaela Colamasi
[email protected] 
+39 348 2314362

SOURCE Bracco Imaging S.p.A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED